These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 27014981)
1. [Role of CXCR4/STAT3 in mesenchymal stromal cell-mediated drug resistance of acute leukemia cells]. Tang Y; Guo Q; Zhi Y; Jin X; Xia B; Guo S; Tian C; Zhang Y Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):119-23. PubMed ID: 27014981 [TBL] [Abstract][Full Text] [Related]
2. [Role of c-Myc in mesenchymal stromal cell-mediated drug resistance in acute leukemia cells]. Xia B; Guo Q; Zhao WP; Guo SQ; Tian C; Zhang YZ Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1746-9. PubMed ID: 24124686 [TBL] [Abstract][Full Text] [Related]
3. [Effects of SDF-1/CXCR4 signal pathway blockade by AMD3100 on the adhesion of leukemia cells to osteoblast niche and the drug resistance of leukemia cells]. Shen Z; Zeng D; Zou Z; Zhu L; Ma Y; Zhang X; Zhang C; Li J; Kong P Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):413-7. PubMed ID: 26031530 [TBL] [Abstract][Full Text] [Related]
4. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824 [TBL] [Abstract][Full Text] [Related]
5. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Sison EA; McIntyre E; Magoon D; Brown P Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844 [TBL] [Abstract][Full Text] [Related]
6. Osteoblasts protect AML cells from SDF-1-induced apoptosis. Kremer KN; Dudakovic A; McGee-Lawrence ME; Philips RL; Hess AD; Smith BD; van Wijnen AJ; Karp JE; Kaufmann SH; Westendorf JJ; Hedin KE J Cell Biochem; 2014 Jun; 115(6):1128-37. PubMed ID: 24851270 [TBL] [Abstract][Full Text] [Related]
7. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221 [TBL] [Abstract][Full Text] [Related]
8. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446 [TBL] [Abstract][Full Text] [Related]
9. [Effects of Gao X; Chu LJ; Yan ZH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):663-669. PubMed ID: 38926951 [TBL] [Abstract][Full Text] [Related]
10. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077 [TBL] [Abstract][Full Text] [Related]
11. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566 [TBL] [Abstract][Full Text] [Related]
12. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254 [TBL] [Abstract][Full Text] [Related]
13. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675 [TBL] [Abstract][Full Text] [Related]
14. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; Apperley J; Lam EW; Dazzi F Haematologica; 2010 Jul; 95(7):1081-9. PubMed ID: 20179085 [TBL] [Abstract][Full Text] [Related]
16. Effects of sitagliptin activation of the stromal cell-derived factor-1/CXC chemokine receptor 4 signaling pathway on the proliferation, apoptosis, inflammation, and osteogenic differentiation of human periodontal ligament stem cells induced by lipopolysaccharide. Tang X; Zhou Z; Li Q; Jiang D Hua Xi Kou Qiang Yi Xue Za Zhi; 2024 Feb; 42(1):37-45. PubMed ID: 38475949 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063 [TBL] [Abstract][Full Text] [Related]
18. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565 [TBL] [Abstract][Full Text] [Related]
19. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955 [TBL] [Abstract][Full Text] [Related]
20. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging. Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]